- Price
- $546.12
- Day
- -2.12%
- Mkt Cap
- $138.61B
- 52W Range
- $374.17 – $560.25
- Volume
- 801.8K
- Beta
- 0.32
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
3 Stocks Whose Competitive Walls Tower Over Nvidia's
Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company's continued growth and diversification. Completion of Acquisition of Crinetic.
17,047 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Beacon Pointe Advisors LLC
Beacon Pointe Advisors LLC purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 17,047 shares of the pharmaceutical company's stock, valued at approximately $8,466,000. A number of other hedge funds have
Ancora Advisors LLC Acquires Shares of 1,127 Vertex Pharmaceuticals Incorporated $VRTX
Ancora Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,127 shares of the pharmaceutical company's stock, valued at approximately $560,000. A number of other institutional investors